a public good project by the
Synthesis
Company
of California

© 2026

Dennis J. Slamon | doi.page

0 works0 citations0 h-index

Dennis J. Slamon

APLA Health(US)University of California, Los Angeles(US)UCLA Health(US)UCLA Health(US)

Publications by Year

Research Areas

HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Lung Cancer Research Studies

Most-Cited Works

→ Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene(1987)11,680 cited
→ Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2(2001)11,439 cited
→ Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer(1989)6,838 cited
→ Palbociclib and Letrozole in Advanced Breast Cancer(2016)2,879 cited
→ Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease(1999)2,788 cited
→ Adjuvant Trastuzumab in HER2-Positive Breast Cancer(2011)2,750 cited

→ Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses(2015)1,942 cited

→ The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study(2014)1,890 cited

→ Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer(2002)1,854 cited

→ Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial(2016)1,795 cited